(CercleFinance.com) – MaaT Pharma shares rose on Monday on the Paris Stock Exchange following the presentation of positive results in blood cancers for its most advanced drug candidate.
The Lyon biotech presented encouraging effectiveness data at the annual conference of the American Society of Hematology (ASH), which is currently being held in the United States.
In 111 patients with acute graft-versus-host disease (aGvHD) treated with MaaT013, the overall gastrointestinal response rate reached 53% after the 28th day, with a significant impact on overall survival ( OS) in responding patients.
The company emphasizes that these results are even more pronounced for the population of patients with a profile similar to those treated in the Phase 3 clinical trial, with a response rate of 61% at day 28.
In a press release, MaaT added that its drug candidate demonstrated a good safety profile and an increase in overall survival, thus strengthening its favorable benefit-risk profile.
Listed on the Paris Stock Exchange, the stock rose by more than 10% after these announcements.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
